Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liang-Hsuan Chen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Hsien-Ming Wu

    Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Medical Center, School of Medicine, Chang Gung University, Taoyuan 333, Taiwan

    12 shared publications
  • Hong-Yuan Huang

    Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Medical Center, 5, Fu-Shin Street, Taoyuan 33301, Taiwan

    5 shared publications
  • Hong-Yuan Huang

    Department of Obstetrics and Gynecology, LinKou Medical Center, Chang Gung Memorial Hospital, Taoyuan City, Taiwan

    4 shared publications
  • Yung-Kuei Soong

    Department of Obstetrics and Gynecology, LinKou Medical Center, Chang Gung Memorial Hospital, Taoyuan City, Taiwan

    4 shared publications
  • Hsin-Shih Wang

    3 shared publications
  • Hsin-Shih Wang

    Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Medical Center, School of Medicine, Chang Gung University, Taoyuan 333, Taiwan

    3 shared publications

Latest Publications

  • Open Access

    RETRACTED: Wu et al. EGF-Enhanced GnRH-II Regulation in Decidual Stromal Cell Motility Through Twist and N-Cadherin Signaling. Int. J. Mol. Sci. 2023, 24, 15271

    by Hsien-Ming Wu, Liang-Hsuan Chen, Hong-Yuan Huang, Hsin-Shih Wang, Chia-Lung Tsai

    The journal retracts the article titled “EGF-Enhanced GnRH-II Regulation in Decidual Stromal Cell Motility through Twist and N-Cadherin Signaling”

  • Open Access

    Smooth endoplasmic reticulum aggregates in oocytes: a comparison of progestin-primed and GnRH antagonist IVF protocols

    by Hsien-Ming Wu, Cindy Hsuan Weng, Yen-Ju Sung, Le-Tien Hsu, Shang-Yu Huang, Chia-Lin Chang, Hong-Yuan Huang, Yung-Kuei Soong, Liang-Hsuan Chen

    Vitrification improves post-thawed embryo recovery and enables new strategies for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). Due to its convenience and efficacy, progestin-primed ovarian stimulation (PPOS) gets more attention in daily practice. However, concerns about the impact of PPOS on oocyte and embryo quality still exist. We aimed to compare the embryological and pregnancy outcomes between PPOS and gonadotropin-releasing hormone (GnRH) antagonist protocol in IVF/ICSI cases. This was a retrospective cohort study of 545 women undergoing IVF/ICSI cycles from July 2017 to December 2018. The patients were allocated into two groups: the PPOS and GnRH antagonist group, based on 1:1 propensity score matching. In both groups, all viable embryos were cryopreserved for later transfer. The primary endpoint was the prevalence of smooth endoplasmic reticulum aggregates (SERa) in oocytes. Secondary outcomes included the cycle characteristics and pregnancy outcomes. Ovarian stimulation duration and serum estradiol level on trigger day were significantly higher in the PPOS group compared to the GnRH antagonist group. The prevalence of SERa + cycles was 9.4% in our cohort (13.0% and 12.2% in the PPOS and GnRH antagonist groups, respectively, p = 0.221). There were more frozen embryos (5.3 ± 4.5 vs. 4.8 ± 4.0, p = 0.378) in the PPOS group than in the GnRH group, particularly for the subgroup of low responders (1.6 ± 1.2 vs. 1.2 ± 1.0, p = 0.043). No significant differences were observed between the groups regarding clinical pregnancy rate, miscarriage, live birth rate, and cumulative live birth rate in the following two years after oocyte retrieval. Our findings suggest that the PPOS protocol provides clinical benefits and safety with comparable oocyte quality and pregnancy outcomes to the GnRH antagonist protocol.

  • Open Access

    The Current Understanding of Molecular Mechanisms in Adenomyosis-Associated Infertility and the Treatment Strategy for Assisted Reproductive Technology

    by Hsien-Ming Wu, Tian-Chi Tsai, Shang-Min Liu, Angel Hsin-Yu Pai, Liang-Hsuan Chen

    Adenomyosis, endometriosis of the uterus, is associated with an increased likelihood of abnormal endometrial molecular expressions thought to impair implantation and early embryo development, resulting in disrupted fertility, including the local effects of sex steroid and pituitary hormones, immune responses, inflammatory factors, and neuroangiogenic mediators. In the recent literature, all of the proposed pathogenetic mechanisms of adenomyosis reduce endometrial receptivity and alter the adhesion molecule expression necessary for embryo implantation. The evidence so far has shown that adenomyosis causes lower pregnancy and live birth rates, higher miscarriage rates, as well as adverse obstetric and neonatal outcomes. Both pharmaceutical and surgical treatments for adenomyosis seem to have a positive impact on reproductive outcomes, leading to improved pregnancy and live birth rates. In addition, adenomyosis has negative impacts on reproductive outcomes in patients undergoing assisted reproductive technology. This association appears less significant after patients follow a long gonadotropin-releasing hormone agonist (GnRHa) protocol, which improves implantation rates. The pre-treatment of GnRHa can also be beneficial before engaging in natural conception attempts. This review aims to discover adenomyosis-associated infertility and to provide patient-specific treatment options.


  • Open Access

    RETRACTED: EGF-Enhanced GnRH-II Regulation in Decidual Stromal Cell Motility through Twist and N-Cadherin Signaling

    by Hsien-Ming Wu, Liang-Hsuan Chen, Hong-Yuan Huang, Hsin-Shih Wang, Chia-Lung Tsai

    Crucial roles in embryo implantation and placentation in humans include the invasion of the maternal decidua by extravillous trophoblasts and the motile behavior of decidual endometrial stromal cells. The effects of the epidermal growth factor (EGF) and GnRH-II in the endometrium take part in early pregnancy. In the present study, we demonstrated the coaction of EGF- and GnRH-II-promoted motility of human decidual endometrial stromal cells, indicating the possible roles of EGF and GnRH-II in embryo implantation and early pregnancy. After obtaining informed consent, we obtained human decidual endometrial stromal cells from decidual tissues from normal pregnancies at 6 to 12 weeks of gestation in healthy women undergoing suction dilation and curettage. Cell motility was evaluated with invasion and migration assays. The mechanisms of EGF and GnRH-II were performed using real-time PCR and immunoblot analysis. The results showed that human decidual tissue and stromal cells expressed the EGF and GnRH-I receptors. GnRH-II-mediated cell motility was enhanced by EGF and was suppressed by the knockdown of the endogenous GnRH-I receptor and EGF receptor with siRNA, revealing that GnRH-II promoted the cell motility of human decidual endometrial stromal cells through the GnRH-I receptor and the activation of Twist and N-cadherin signaling. This new concept regarding the coaction of EGF- and GnRH-promoted cell motility suggests that EGF and GnRH-II potentially affect embryo implantation and the decidual programming of human pregnancy.


  • Top Cited Papers
    Open Access

    A Lifelong Impact on Endometriosis: Pathophysiology and Pharmacological Treatment

    by Liang-Hsuan Chen, Wei-Che Lo, Hong-Yuan Huang, Hsien-Ming Wu

    Endometriosis is a chronic inflammatory disease associated with bothersome symptoms in premenopausal women and is complicated with long-term systemic impacts in the post-menopausal stage. It is generally defined by the presence of endometrial-like tissue outside the uterine cavity, which causes menstrual disorders, chronic pelvic pain, and infertility. Endometriotic lesions can also spread and grow in extra-pelvic sites; the chronic inflammatory status can cause systemic effects, including metabolic disorder, immune dysregulation, and cardiovascular diseases. The uncertain etiologies of endometriosis and their diverse presentations limit the treatment efficacy. High recurrence risk and intolerable side effects result in poor compliance. Current studies for endometriosis have paid attention to the advances in hormonal, neurological, and immunological approaches to the pathophysiology and their potential pharmacological intervention. Here we provide an overview of the lifelong impacts of endometriosis and summarize the updated consensus on therapeutic strategies.


  • Open Access

    Endothelial dysfunction in subfertile women with polycystic ovary syndrome

    by Liang-Hsuan Chen, Chia-Pin Lin, Hsien-Ming Wu, Po-Hsien Chu


  • Open Access

    Altered Expression of Interleukin-18 System mRNA at the Level of Endometrial Myometrial Interface in Women with Adenomyosis

    by Liang-Hsuan Chen, She-Hung Chan, Chin-Jung Li, Hsien-Ming Wu, Hong-Yuan Huang

    Adenomyosis is a uterine pathology characterized by a deep invasion of endometrial glands and stroma, disrupting the endometrial–myometrial interface (EMI). Interleukin-18 (IL-18) system is a dominant cytokine involved in the menstrual cycle of human endometrium. IL-18 may play a defensive role against maternal immune response in the uterine cavity. The present study was designed to determine IL-18-mediated immune response at the level of EMI. We uncovered that mRNA of IL-18 system, including IL-18, IL-18 receptor (IL-18R), and its antagonist, IL-18 binding protein (IL-18BP), expressed in eutopic, ectopic endometrium, and corresponding myometrium in patients with adenomyosis. IL-18 system was demonstrated in paired tissue samples by immunochemistry and immunofluorescence study. According to RT-PCR with CT value quantification and 2−∆∆Ct method, a significant down-regulation of IL-18BP in corresponding myometrium in comparison to eutopic endometrium (p < 0.05) indicates that the IL-18 system acts as a local immune modulator at the level of EMI and regulating cytokine networks in the pathogenesis of adenomyosis. Furthermore, an increased IL-18 antagonist to agonist ratio was noted in ectopic endometrium compared with corresponding myometrium. We suggest that altered IL-18 system expression contributes to immunological dysfunction and junctional zone disturbance in women with adenomyosis.


  • Open Access

    Immune Tolerance of Embryo Implantation and Pregnancy: The Role of Human Decidual Stromal Cell- and Embryonic-Derived Extracellular Vesicles

    by Hsien-Ming Wu, Liang-Hsuan Chen, Le-Tien Hsu, Chyong-Huey Lai

    Embryo–endometrial communication plays a critical role in embryo implantation and the establishment of a successful pregnancy. Successful pregnancy outcomes involve maternal immune modulation during embryo implantation. The endometrium is usually primed and immunomodulated by steroid hormones and embryo signals for subsequent embryo implantation and the maintenance of pregnancy. The roles of extracellular vesicles (EVs) and microRNAs for the embryo–maternal interactions have been elucidated recently. New evidence shows that endometrial EVs and trophectoderm-originated EV cargo, including microRNAs, proteins, and lipids in the physiological microenvironment, regulate maternal immunomodulation for embryo implantation and subsequent pregnancy. On the other hand, trophoblast-derived EVs also control the cross-communication between the trophoblasts and immune cells. The exploration of EV functions and mechanisms in the processes of embryo implantation and pregnancy will shed light on a practical tool for the diagnostic or therapeutic approaches to reproductive medicine and infertility.


  • Open Access

    Extracellular Vesicle-Associated MicroRNA-138-5p Regulates Embryo Implantation and Early Pregnancy by Adjusting GPR124

    by Hsien-Ming Wu, Tzu-Chi Lo, Chia-Lung Tsai, Liang-Hsuan Chen, Hong-Yuan Huang, Hsin-Shih Wang, John Yu

    Functional embryo–maternal interactions occur during the embryo implantation and placentation. Extracellular vesicles with microRNA (miR) between cells have been considered of critical importance for embryo implantation and the programming of human pregnancy. MiR-138-5p functions as the transcriptional regulator of G protein-coupled receptor 124 (GPR124). However, the signaling pathway of miR138-5p- and GPR124-adjusted NLRP3 inflammasome activation remains unclear. In this study, we examine the roles of the miR138-5p and GPR124-regulated inflammasome in embryo implantation and early pregnancy. Human decidual stromal cells were isolated from the abortus tissue and collected by curettage from missed abortion patients and normal pregnant women at 6- to 12-week gestation, after informed consent. Isolated extracellular vesicles from decidua and decidual stromal cells were confirmed by transmission electron microscopy (TEM). Next-Generation Sequencing (NGS) and microarray were performed for miR analysis. The predicated target genes of the differentially expressed miR were analyzed to identify the target genes and their pathway. We demonstrated the down-regulation of miR-138-5p and the overexpression of GPR124 in spontaneous miscarriage compared to normal pregnancy. We also showed the excessive activation of the NLRP3 inflammasome in spontaneous miscarriage compared to normal pregnancy. Here, we newly demonstrate that the miR-138-5p and GPR124-adjusted NLRP3 inflammasome were expressed in extracellular vesicles derived from decidua and decidual stromal cells, indicating that the miR-138-5p, GPR124 and NLRP3 (NACHT, LRR, and PYD domains-containing protein 3) inflammasome have a potential modulatory role on the decidual programming and placentation of human pregnancy. Our findings represent a new concept regarding the role of extracellular vesicles, miR-138-5p, GPR124, and the NLRP3 inflammasome in normal early pregnancy and spontaneous miscarriage.


  • Impact of growth hormone-releasing hormone antagonist on decidual stromal cell growth and apoptosis in vitro

    by Hsien-Ming Wu, Liang-Hsuan Chen, Andrew V Schally, Hong-Yuan Huang, Yung-Kuei Soong, Peter C K Leung, Hsin-Shih Wang

    Endometrial stromal cells remodeling is critical during human pregnancy. Growth hormone-releasing hormone and its functional receptor have been shown to be expressed in gynecological cancer cells and eutopic endometrial stromal cells. Recent studies have demonstrated the potential clinical uses of antagonists of growth hormone-releasing hormone as effective antitumor agents because of its directly antagonistic effect on the locally produced growth hormone-releasing hormone in gynecological tumors. However, the impact of growth hormone-releasing hormone antagonists on normal endometrial stromal cell growth remained to be elucidated. The aim of this study was to investigate the effect of a growth hormone-releasing hormone antagonist (JMR-132) on cell proliferation and apoptosis of human decidual stromal cells and the underlying molecular mechanisms. Our results showed that growth hormone-releasing hormone and the splice variant 1 of growth hormone-releasing hormone receptor are expressed in human decidual stromal cells isolated from the decidual tissues of early pregnant women receiving surgical abortion. In addition, treatment of stroma cells with JMR-132 induced cell apoptosis with increasing cleaved caspase-3 and caspase-9 activities and decrease cell viability in a time- and dose-dependent manner. Using a dual inhibition approach (pharmacological inhibitors and siRNA-mediated knockdown), we showed that JMR-132-induced activation of apoptotic signals are mediated by the activation of ERK1/2 and JNK signaling pathways and the subsequent upregulation of GADD45alpha. Taken together, JMR-132 suppresses cell survival of decidual stromal cells by inducing apoptosis through the activation of ERK1/2- and JNK-mediated upregulation of GADD45alpha in human endometrial stromal cells. Our findings provide new insights into the potential impact of growth hormone-releasing hormone antagonist on the decidual programming in humans.